⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 16, 2024Open Access

Supplementary Figure S1 from TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer

Alban Bessede Florent Peyraud Benjamin Besse Sophie Cousin Mathilde Cabart François Chomy Christophe Rey Oren Lara Ophélie Odin Imane Nafia Lucile Vanhersecke Fabrice Barlési Jean‐Philippe Guégan Antoîne Italiano

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 1. TACSTD2 gene expression predicts response to IO independently of PD-L1 status

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bessede et al. (2024) studied this question.

synapsesocial.com/papers/68e78e41b6db6435877002c4 https://doi.org/10.1158/1078-0432.25232290

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer2024
2Supplementary Figure S2 from TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer2024
3Supplementary Figure S2 from TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer2024
4Data from TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer2024 · 1 citations
5Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy2025 · 6 citations

More related papers

Figure S1 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer2024
Genomic, immunologic, and prognostic associations of TROP2 (<i>TACSTD2</i>) expression in solid tumors2024
Abstract 391: TROP2 and PTEN are biomarkers of primary resistance to <i>TUSC2</i> gene therapy in non-small cell lung cancer (NSCLC).2026